Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20016963 | 0.84 | ALDH1A1 (0.43) | MEN1KMT2APOLBMAPTHPGD | |
| SCHEMBL23267598 | 0.82 | ALDH1A1 (0.53) | MEN1KMT2AMAPTHPGDNPC1 | |
| SCHEMBL3663914 | 0.80 | MEN1 (0.81) | MEN1KMT2APOLBMAPTHPGD | |
| SCHEMBL26286612 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2APOLBMAPTHPGD | |
| SCHEMBL30643718 | 0.78 | L3MBTL1 (0.52) | MEN1KMT2APOLBMAPTHPGD | |
| SCHEMBL24456618 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2APOLBMAPTHPGD | |
| SCHEMBL20233005 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2APOLBMAPTHPGD | |
| SCHEMBL12542224 | 0.78 | POLB (0.51) | MEN1KMT2APOLBNPC1ALDH1A1 | |
| SCHEMBL20034969 | 0.78 | MEN1 (0.71) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL1726021 | 0.78 | L3MBTL1 (0.68) | POLBHPGDNPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-9018244-B2 | Benzopyran compounds, compositions and uses thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| WO-2014203132-A1 | SUBSTITUTED BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014203129-A1 | COMBINATIONS OF BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013090921-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | ESR2, GPER1, ESR1 | MEN1 4303/4885KMT2A 2438/4885POLB 4014/4885 |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | ESR2, GPER1, ESR1 | MEN1 4303/4885KMT2A 2438/4885POLB 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.